Fluconazole 150mg Tablets are a solid oral pharmaceutical formulation containing Fluconazole as the active pharmaceutical ingredient at a strength of 150mg per tablet. Development of this dosage form requires careful evaluation of API characteristics, excipient compatibility, powder flow, blend uniformity, compression performance, and finished-product specifications. A controlled manufacturing process helps maintain consistency across individual tablets and production batches. For pharmaceutical companies expanding their solid dosage portfolio, Fluconazole 150mg Tablets can be incorporated into a structured PCD Pharma Franchise range supported by appropriate technical specifications, quality systems, and packaging documentation.
Formulation development begins with assessment of Fluconazole's physical and chemical characteristics. Parameters such as particle size, bulk density, flowability, moisture content, and compressibility may influence the selection of suitable excipients and manufacturing technology.
The tablet formulation may contain pharmaceutical-grade diluents, binders, disintegrants, glidants, lubricants, and other functional excipients depending on the approved composition. Diluents can help establish the required tablet weight, while binders may contribute to granule formation and tablet strength. Disintegrants can be selected according to the desired tablet performance, while glidants and lubricants assist in powder processing and compression.
Compatibility studies between Fluconazole and the proposed excipient system can be performed during preformulation. Such studies may assess potential physical or chemical interactions under controlled conditions.
The final formulation is established after evaluating important characteristics such as powder behavior, tablet hardness, friability, disintegration, dissolution, appearance, and stability. A suitable formulation architecture aims to provide consistent API distribution and reproducible tablet performance.
Manufacturing begins with controlled receipt, identification, testing, and dispensing of Fluconazole and all approved excipients. Each material is weighed according to the authorized batch manufacturing formula and verified through established procedures.
Depending on the characteristics of the raw materials, sieving or milling may be performed to achieve a suitable particle-size distribution. Consistent particle characteristics can improve powder flow and help reduce segregation during processing.
The blending process is designed to distribute Fluconazole uniformly throughout the excipient matrix. The sequence of ingredient addition, mixer loading, blending time, and mixing speed can influence blend uniformity and therefore need to be established during formulation development.
If granulation is selected, the preblend may undergo a controlled granulation process followed by drying and sizing. Drying parameters are monitored to achieve an appropriate moisture level and suitable granule properties.
Representative samples may be collected from different locations within the final blend and evaluated according to an approved sampling procedure. Controlled material transfer from the blending stage to compression helps minimize segregation and maintain batch uniformity.
The prepared final blend or granules are transferred to the tablet compression stage. Depending on the formulation characteristics, direct compression or granulation-based compression may be used.
Compression parameters such as machine speed, compression force, feeder settings, and tooling configuration are established according to the validated manufacturing process. These parameters can influence tablet weight, thickness, hardness, friability, and overall appearance.
In-process testing may include weight variation, thickness, hardness, friability, and visual inspection. Monitoring these attributes throughout compression helps identify process variations at an early stage.
Fluconazole 150mg Tablets may be produced as plain or film-coated tablets according to the approved product design. Where film coating is used, coating parameters such as suspension preparation, spray rate, pan speed, drying conditions, and coating weight gain are controlled.
The compression process should produce tablets with consistent physical characteristics and adequate mechanical integrity for subsequent handling and packaging.
Process parameters and in-process observations are documented in the batch manufacturing record, providing traceability throughout the production cycle.
Quality-control testing for Fluconazole 150mg Tablets includes evaluation of the active pharmaceutical ingredient and relevant physical and performance characteristics.
Identification and assay testing can be performed using appropriate validated analytical procedures to confirm the identity and specified quantity of Fluconazole. Dosage-unit uniformity can also be evaluated to confirm consistency between individual tablets.
Dissolution testing may be performed under predefined laboratory conditions to assess the release characteristics of the finished dosage form. The analytical method should be capable of accurately evaluating Fluconazole without interference from formulation excipients or potential degradation products.
Depending on the approved specification, additional tests may include disintegration, hardness, friability, weight variation, thickness, moisture content, appearance, and related substances.
Analytical procedures should be appropriately validated or qualified for their intended purpose. Laboratory instruments should be qualified, calibrated, and maintained according to established quality procedures.
Visual inspection may also be used to identify physical defects such as cracks, chipped edges, discoloration, coating irregularities, or other unacceptable characteristics.
All laboratory results, raw data, calculations, and instrument records should be documented and reviewed as part of the batch-release process.
Stability evaluation is performed to determine whether Fluconazole 150mg Tablets maintain their established quality characteristics throughout the proposed shelf life. Stability studies may monitor assay, dissolution, degradation products, physical appearance, moisture-related parameters, and other relevant quality attributes.
The product may be evaluated under defined long-term and accelerated stability conditions. Such studies help assess the influence of temperature, humidity, light, and other environmental factors on the finished formulation.
Packaging selection is based on the product's stability profile and required protection during storage and transportation. Suitable pharmaceutical-grade blister packs, strips, or other approved container systems may be considered.
Packaging compatibility studies can evaluate potential interaction between the tablet formulation and primary packaging materials. Seal integrity and barrier characteristics may also be assessed where relevant.
The final packaging should maintain product integrity throughout distribution and handling. Product labeling should include the approved product name, composition, strength, batch number, manufacturing details, expiry information, storage requirements, and other applicable regulatory particulars.
Stability data generated during development can support the determination of shelf life and appropriate storage conditions.
Fluconazole 150mg Tablets can be integrated into a broader pharmaceutical tablet portfolio through standardized formulation development, controlled manufacturing, analytical testing, and appropriate packaging systems. For businesses operating in the PCD Pharma Franchise sector, maintaining consistent technical specifications can support organized product management across different markets.
A structured product-development file may include raw-material specifications, supplier qualification documents, formulation composition, manufacturing instructions, in-process control parameters, analytical methods, finished-product specifications, packaging details, and stability-study records.
Quality management should extend from raw-material procurement through dispensing, blending, granulation where applicable, compression, coating, packaging, laboratory testing, and final batch release.
Process validation can help establish that defined manufacturing parameters consistently produce tablets meeting established quality specifications. Equipment qualification, change control, deviation management, and standard operating procedures further support manufacturing consistency.
For commercial portfolio management, the product's composition and strength should remain consistent across packaging artwork, technical documentation, catalogs, and digital product listings.
Overall, Fluconazole 150mg Tablets require coordinated control over API characterization, excipient compatibility, powder processing, blend uniformity, tablet compression, finished-product testing, dissolution, stability, and packaging. A systematic pharmaceutical quality framework across these stages supports the development of a consistent and professionally documented finished tablet suitable for inclusion in a broader PCD Pharma Franchise portfolio.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech